300+ investors in your industry, stage, and region Get
Any industry
Hospitality
Video Games
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
Energy
SaaS
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Wellness
Education
Medical Device
Automotive
eSports
Sports
Legal
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Medical
Web3
Theatre
Recruiting
Crowdfunding
Infrastructure
Venture Capital
Beauty
Fashion
Social
Celebrity
LGBT
Climate
Cannabis
Wine and Spirits
Mobile Apps
Life Science
Food and Beverage
Publishing
Art
Music
Real Estate
Sporting Goods
FinTech
Finance
Digital Media
Manufacturing
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Sustainability
Proptech
Hardware
Impact
Transportation
Biotech
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
Japan
South Korea
Singapore
Burkina Faso
LATAM
Brazil
Africa
Gibraltar
Egypt
Oceania
Taiwan
Zimbabwe
Tunisia
Sweden
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Kyrgyzstan
Haiti
Norway
Lesotho
Liberia
Isle of Man
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Poland
Oman
Puerto Rico
Guernsey
Cameroon
Costa Rica
Colombia
China
Armenia
Czech Republic
Kuwait
Marshall Islands
Malta
Luxembourg
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Jamaica
Sri Lanka
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Uganda
Myanmar
Turkey
Uruguay
Morocco
Moldova
Seychelles
Botswana
France
Paraguay
South Africa
Denmark
Georgia
Ghana
Iraq
Portugal
Philippines
Sierra Leone
El Salvador
Senegal
Germany
India
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Bermuda
Middle East
Dominican Republic
Albania
Asia
Angola
Europe
Argentina
Bangladesh
Barbados
Cyprus
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Faroe Islands
Spain
Estonia
Bahrain
Bahamas
Jersey
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Israel
Grenada
Honduras
Iceland
Lithuania
Cambodia
Liechtenstein
Lebanon
Mongolia
Qatar
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Synthesis Capital, VC Fund

Synthesis Capital

VC Fund

London, United Kingdom

Synthesis Capital is an investment manager transforming our food system through food technology.

Total investments:
12
Last investment:
Lead investor:
50%
Fund size:
$300M
Last fund:

Last updated:

Industries Synthesis Capital invests in

Food and BeverageBiotechnologyFood ProcessingOrganic FoodSustainability

Stages Synthesis Capital invests in

Series CSeedSeries AVenture - Series UnknownSeries B

Countries Synthesis Capital invests in

United StatesIsraelAustria

Round sizes

Seed $7.1M–$9MSeries A $20M–$23MSeries C $160M–$400M

Contacts

NameEmailPhoneSocials

Sign up to unlock verified contacts

Unlock Contacts

Round size

Seed
$7.1M–$9M
Series A
$20M–$23M
Series C
$160M–$400M

Investment Focus

Industry

  • Food and Beverage 7 (58%)
  • Biotechnology 6 (50%)
  • Food Processing 5 (42%)
  • Organic Food 3 (25%)
  • Sustainability 3 (25%)
See all 15 industries →

Stage

  • Series C 3 (25%)
  • Seed 2 (17%)
  • Series A 2 (17%)
  • Venture - Series Unknown 2 (17%)
  • Series B 1 (8%)
See all 7 stages →

Country

  • United States 7 (58%)
  • Israel 2 (17%)
  • Austria 1 (8%)

Team

NameTitleInvestmentsLinksEmail
Constantinos Yiannoulis
Constantinos Yiannoulis Managing Partner and Co - Founder
Managing Partner and Co - Founder Total investments: 3
Find email
Rosie Wardle
Rosie Wardle Co-Founder and Partner
Co-Founder and Partner Total investments: 4
Find email

Investments

CompanyDescriptionRoundLinks
Savor is transforming how fats and oils are produced for food. By using carbon-based feedstocks like CH4 and CO2, they create animal-equivalent alternatives that aim to decarbonize the 7% of global greenhouse gas emissions tied to traditional fat and oil production. Their first product, an animal-free butter launched in 2025 and is alreadygenerating excitement among chefs and food industry leaders. $23M / Series A / Feb 09, 2024
Triplebar provides sustainability, biotechnology, and synthetic biology research. Oct 25, 2023
Triplebar provides sustainability, biotechnology, and synthetic biology research. $20M / Series A / Oct 25, 2023
Hyfé Foods is a biotech company producing ingredients by leveraging fungal fermentation to upcycle water byproducts from food manufacturers. $9M / Seed / Jun 22, 2023
Equinom is a fully integrated food-tech company, combining agricultural know-how, culinary expertise, and deep technology to develop delicious, nutritious, affordable, and sustainable non-GMO plant-based ingredients – from the ground up.For decades, crops have been farmed primarily for animal feed – not for human consumption. To be palatable inhuman food, these crops require extensive and expensive processing. . With limited processing facilities equipped for this use, the industry is on track to supply only 50% of the projected demand for plant-based foods.What is Equinom doing about it? Equinom is using science and technology to develop superior ingredients naturally, at the source – in a fraction of the time typically required to breed new crops. Equinom crops are bred naturally, without genetic editing or modification, and are optimized to make meat and dairy analogs more delicious, nutritious, cost-effective, and sustainable. The company’s proprietary Manna™ technology platform uses AI to speed the development of superior, high-yield, non-GMO ingredients as nature intended – featuring quality traits that satisfy consumer expectations. The technology also ensures biodiversity and climate resilience which are critical to ensure food security in light of climate change. Working with great partners including Meatless Farm, Roquette with GoodMills Group., Equinom is recognized as a trusted developer and supplier of unrivaled ingredients. Prestigious strategic investors such as BASF and Roquette have helped position Equinom as one of the breakout Round C companies to fuel the worldwide surge in plant-based eating. $35M / Series D / Dec 12, 2022
Mozza engages in developing the science to create real dairy cheese from plants. Its mission is to make cheese from plants that are indistinguishable from cheese that comes from animals. The company was founded in 2018 and is headquartered in Los Angeles, California. $9.4M / Venture - Series Unknown / Jun 14, 2022
UPSIDE Foods (formerly known as Memphis Meats) develops meat produced directly from animal cells without the need to raise and slaughter actual animals. This approach requires significantly less water, land, and energy than conventional meat production, enabling consumers to enjoy meat that is clean, humane, and free of harmful chemicals.Co-founded and led by Dr. Uma Valeti in 2015, UPSIDE Foods is headquartered in Berkeley, California. $400M / Series C / Apr 21, 2022
Arkeon Bio is a biotechnology company that captures CO2 from industry and converts inorganic gases into organic food. $7.1M / Seed / Mar 04, 2022
Redefine Meat uses 3D printing technology, meat digital modeling, and food formulations to produce animal-free meat. Redefine Meat technology produces animal-free meat with the same appearance, texture, and flavor of animal meat, from natural and sustainable ingredients. It was founded in 2018 and headquartered in Tel Aviv, Israel. $135M / Venture - Series Unknown / Jan 23, 2022
Culture Biosciences provides a platform of cloud-connected bioreactors, software tools, and process development services that support upstream bioprocess development for biotech and biopharma applications. The company’s offerings include remote experiment design, monitoring, and data analysis through an integrated cloud software interface pairedwith single-use bioreactors for microbial fermentation and cell culture experimentation. Its services encompass clone and strain screening, process optimization, characterization, and bioprocess modeling to help scientific teams refine and scale their workflows. Clients access real-time data and analytics to inform decisions and collaborate across teams using the platform’s tools. Culture Biosciences’s technology is used to advance development of therapeutics, synthetic biology products, and related bioprocesses. Culture Biosciences was founded in 2016 and is headquartered in San Francisco, California. $80M / Series B / Oct 14, 2021
See all 12 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Hospitality
Video Games
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
Energy
SaaS
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Wellness
Education
Medical Device
Automotive
eSports
Sports
Legal
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Medical
Web3
Theatre
Recruiting
Crowdfunding
Infrastructure
Venture Capital
Beauty
Fashion
Social
Celebrity
LGBT
Climate
Cannabis
Wine and Spirits
Mobile Apps
Life Science
Food and Beverage
Publishing
Art
Music
Real Estate
Sporting Goods
FinTech
Finance
Digital Media
Manufacturing
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Sustainability
Proptech
Hardware
Impact
Transportation
Biotech
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
Japan
South Korea
Singapore
Burkina Faso
LATAM
Brazil
Africa
Gibraltar
Egypt
Oceania
Taiwan
Zimbabwe
Tunisia
Sweden
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Kyrgyzstan
Haiti
Norway
Lesotho
Liberia
Isle of Man
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Poland
Oman
Puerto Rico
Guernsey
Cameroon
Costa Rica
Colombia
China
Armenia
Czech Republic
Kuwait
Marshall Islands
Malta
Luxembourg
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Jamaica
Sri Lanka
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Uganda
Myanmar
Turkey
Uruguay
Morocco
Moldova
Seychelles
Botswana
France
Paraguay
South Africa
Denmark
Georgia
Ghana
Iraq
Portugal
Philippines
Sierra Leone
El Salvador
Senegal
Germany
India
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Bermuda
Middle East
Dominican Republic
Albania
Asia
Angola
Europe
Argentina
Bangladesh
Barbados
Cyprus
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Faroe Islands
Spain
Estonia
Bahrain
Bahamas
Jersey
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Israel
Grenada
Honduras
Iceland
Lithuania
Cambodia
Liechtenstein
Lebanon
Mongolia
Qatar
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Synthesis Capital invest in?

Synthesis Capital invests primarily in Food and Beverage, Biotechnology and Food Processing startups, most often at Series C and Seed stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What round sizes does Synthesis Capital invest in?

Synthesis Capital typically joins rounds of $7.1M–$9M at Seed, $20M–$23M at Series A and $160M–$400M at Series C. These are whole funding-round sizes, not Synthesis Capital's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Synthesis Capital took part in.

How do I contact Synthesis Capital?

Public channels for Synthesis Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at Synthesis Capital?

The team at Synthesis Capital includes Constantinos Yiannoulis (Managing Partner and Co - Founder) and Rosie Wardle (Co-Founder and Partner). The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Synthesis Capital Synthesis Capital Find emails